Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 377 publications
The Geography of Pharmaceutical Innovation: The US and China in a New World Order.
Journal: JAMA
Published: March 26, 2026
Oncology Drug Development: Challenges of Increasingly Available Therapies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 04, 2026
Project 5 in 5: Paving the Way for Increasing Pragmatism in Clinical Oncology Trials.
Journal: JCO oncology practice
Published: January 09, 2026
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 31, 2025
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 24, 2025
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 06, 2025
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 24, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 22, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 05, 2025
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 28, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 19, 2025
Last Updated: 09/26/2026